New nanodrug to treat sepsis by modulating the immune response
Official title: Bioactive immune-modulating nanodrug for sepsis treatment
Funded at Upstate Medical University · NIH-11076292 · Data updated 2026-11-12
This study is testing a new tiny drug that helps the immune system work better for people with sepsis, a serious condition caused by infections, by capturing harmful signals in the body to reduce inflammation and improve recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | May 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $407,500 |
| NIH project number | 5R35GM153495-02 |
| Project ID | NIH-11076292 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with sepsis or severe infections that lead to hyperinflammation.
✕Less likely to help
Patients with mild infections or those who do not exhibit signs of sepsis may not benefit from this research.
What this research studies
This research focuses on developing a novel nanodrug designed to modulate the immune response in patients suffering from sepsis, a life-threatening condition caused by overwhelming infections. The approach involves using a specialized nanocarrier that can capture harmful inflammatory signals in the body, helping to restore normal immune function. By targeting specific inflammatory mediators, this treatment aims to reduce hyperinflammation and improve patient outcomes. The research will involve testing this nanodrug in preclinical models to assess its effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves survival rates and recovery for patients with sepsis.
How similar studies have gone: Previous research has shown promise in using nanotechnology for drug delivery and immune modulation, suggesting potential for success in this novel approach.
Where this research is happening
-
Upstate Medical University
Syracuse, United States Active
Researchers
- Principal investigator: Luo, Juntao — Upstate Medical University
- Study coordinator: Luo, Juntao
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.